{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"≥ 1 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"≥ 1 TEAE Related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"≥ 1 NCI CTCAE Grade (GR) 3 or Greater TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"≥ 1 NCI CTCAE ≥ GR 3 TEAE Related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"≥ 1 Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"≥ 1 Serious TEAE Related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"≥ 1 TEAE Leading to Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"≥ 1 Related TEAE Leading to Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"≥ 1 TEAE Leading to Dose Reduction/Interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"≥ 1 related TEAE Leading to Decrease/Interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"≥ 1 TEAE Resulting in Death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the start of study treatment and within 28 days after the last dose. Severity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Life-threatening and Grade 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.","groups":[{"description":"Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"NUMBER","populationDescription":"Safety population was defined as all participants who received at least one dose of lenalidomide. All safety analyses were based on the safety population.","reportingStatus":"POSTED","timeFrame":"From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks","title":"Number of Participants With Treatment Emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}